secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001213900-24-060156
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Therapeutics fixes purchase price error, adds employee warrants in merger with ARCA
--------------------------------------------------------------------------------

- July 3, 2024: Oruka and parties signed Letter Agreement correcting a scrivener's error in the Purchase Price definition.
- Same day: Oruka entered an Amended and Restated Subscription Agreement adding warrants for certain employees and service providers.
- Both actions relate to the pending merger with ARCA biopharma (ABIO) under the April 3, 2024 Merger Agreement.
- No changes to the $275M aggregate subscription amount or other key deal terms; corrections are procedural.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390024060156/0001213900-24-060156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea0209134-8k425_arcabio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-060156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer